Literature DB >> 14667264

Glucocorticoid-remediable aldosteronism.

Graham T McMahon1, Robert G Dluhy.   

Abstract

Glucocorticoid remediable aldosteronism (GRA) appears to be the most common monogenic form of human hypertension. As a result of chimeric gene duplication, aldosterone is ectopically synthesized in the zona fasciculata of the adrenal gland under the control of adrenocorticotropin (ACTH). Affected individuals are typically hypertensive, often with onset in youth, and demonstrate refractoriness to standard antihypertensives such as angiotensin-converting enzyme inhibitors and beta-blockers. GRA subjects are normokalemic but often develop hypokalemia when treated with a potassium-wasting diuretic. Analysis of affected kindreds has demonstrated a high prevalence of early cerebral hemorrhage, largely as a result of aneurysms. Identification of affected individuals should allow direct neurovascular screening and targeted antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14667264     DOI: 10.1097/01.crd.0000096417.42861.ce

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  12 in total

Review 1.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.

Authors:  Jennifer J DuPont; Iris Z Jaffe
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

Review 2.  Aldosterone: good guy or bad guy in cerebrovascular disease?

Authors:  Christiné S Rigsby; William E Cannady; Anne M Dorrance
Journal:  Trends Endocrinol Metab       Date:  2005-10-06       Impact factor: 12.015

3.  Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension.

Authors:  Christiné S Rigsby; Adviye Ergul; Vera Portik Dobos; David M Pollock; Anne M Dorrance
Journal:  Am J Hypertens       Date:  2011-02-24       Impact factor: 2.689

4.  A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I.

Authors:  C A Carvajal; C B Stehr; P A González; E M Riquelme; T Montero; M J Santos; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2010-07-13       Impact factor: 4.256

5.  Resistant hypertension and undiagnosed primary hyperaldosteronism detected by use of a computerized database.

Authors:  Emmeline A Garcia; Julio R Lopez; Joy L Meier; Arthur L M Swislocki; David Siegel
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-28       Impact factor: 3.738

6.  11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia.

Authors:  Jessica M Osmond; Anne M Dorrance
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

7.  Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.

Authors:  Shu Liu; Zhongwen Xie; Alan Daugherty; Lisa A Cassis; Kevin J Pearson; Ming C Gong; Zhenheng Guo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-09       Impact factor: 8.311

Review 8.  Is the mineralocorticoid receptor a potential target for stroke prevention?

Authors:  Jessica M Osmond; Christine' S Rigsby; Anne M Dorrance
Journal:  Clin Sci (Lond)       Date:  2008-01       Impact factor: 6.124

9.  Cerebrovascular consequences of pseudohyperaldosteronism.

Authors:  Jonathan H Smith; Noralane M Lindor; Alejandro A Rabinstein
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-03       Impact factor: 3.738

10.  Low renin hypertension.

Authors:  Manisha Sahay; Rakesh K Sahay
Journal:  Indian J Endocrinol Metab       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.